Urine Cotinine Underestimates Exposure to the Tobacco-Derived Lung Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone in Passive Compared with Active Smokers

  • Neal Benowitz
    Authors' Affiliations: 1Division of Clinical Pharmacology and Experimental Therapeutics, Departments of Medicine and Bioengineering and Therapeutic Sciences, 2Center for Tobacco Control Research and Education, 3Division of Occupational and Environmental Medicine and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California; 4Department of General and Analytical Chemistry, Medical University of Silesia, Sosnowiec, Poland; and 5Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública de México, México, D.F., Mexico
  • Maciej Lukasz Goniewicz
    Authors' Affiliations: 1Division of Clinical Pharmacology and Experimental Therapeutics, Departments of Medicine and Bioengineering and Therapeutic Sciences, 2Center for Tobacco Control Research and Education, 3Division of Occupational and Environmental Medicine and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California; 4Department of General and Analytical Chemistry, Medical University of Silesia, Sosnowiec, Poland; and 5Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública de México, México, D.F., Mexico
  • Mark D. Eisner
    Authors' Affiliations: 1Division of Clinical Pharmacology and Experimental Therapeutics, Departments of Medicine and Bioengineering and Therapeutic Sciences, 2Center for Tobacco Control Research and Education, 3Division of Occupational and Environmental Medicine and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California; 4Department of General and Analytical Chemistry, Medical University of Silesia, Sosnowiec, Poland; and 5Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública de México, México, D.F., Mexico
  • Eduardo Lazcano-Ponce
    Authors' Affiliations: 1Division of Clinical Pharmacology and Experimental Therapeutics, Departments of Medicine and Bioengineering and Therapeutic Sciences, 2Center for Tobacco Control Research and Education, 3Division of Occupational and Environmental Medicine and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California; 4Department of General and Analytical Chemistry, Medical University of Silesia, Sosnowiec, Poland; and 5Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública de México, México, D.F., Mexico
  • Wioleta Zielinska-Danch
    Authors' Affiliations: 1Division of Clinical Pharmacology and Experimental Therapeutics, Departments of Medicine and Bioengineering and Therapeutic Sciences, 2Center for Tobacco Control Research and Education, 3Division of Occupational and Environmental Medicine and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California; 4Department of General and Analytical Chemistry, Medical University of Silesia, Sosnowiec, Poland; and 5Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública de México, México, D.F., Mexico
  • Bartosz Koszowski
    Authors' Affiliations: 1Division of Clinical Pharmacology and Experimental Therapeutics, Departments of Medicine and Bioengineering and Therapeutic Sciences, 2Center for Tobacco Control Research and Education, 3Division of Occupational and Environmental Medicine and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California; 4Department of General and Analytical Chemistry, Medical University of Silesia, Sosnowiec, Poland; and 5Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública de México, México, D.F., Mexico
  • Andrzej Sobczak
    Authors' Affiliations: 1Division of Clinical Pharmacology and Experimental Therapeutics, Departments of Medicine and Bioengineering and Therapeutic Sciences, 2Center for Tobacco Control Research and Education, 3Division of Occupational and Environmental Medicine and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California; 4Department of General and Analytical Chemistry, Medical University of Silesia, Sosnowiec, Poland; and 5Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública de México, México, D.F., Mexico
  • Christopher Havel
    Authors' Affiliations: 1Division of Clinical Pharmacology and Experimental Therapeutics, Departments of Medicine and Bioengineering and Therapeutic Sciences, 2Center for Tobacco Control Research and Education, 3Division of Occupational and Environmental Medicine and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California; 4Department of General and Analytical Chemistry, Medical University of Silesia, Sosnowiec, Poland; and 5Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública de México, México, D.F., Mexico
  • Peyton Jacob
    Authors' Affiliations: 1Division of Clinical Pharmacology and Experimental Therapeutics, Departments of Medicine and Bioengineering and Therapeutic Sciences, 2Center for Tobacco Control Research and Education, 3Division of Occupational and Environmental Medicine and Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California; 4Department of General and Analytical Chemistry, Medical University of Silesia, Sosnowiec, Poland; and 5Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública de México, México, D.F., Mexico

書誌事項

公開日
2010-11-01
DOI
  • 10.1158/1055-9965.epi-10-0497
公開者
American Association for Cancer Research (AACR)

この論文をさがす

説明

<jats:title>Abstract</jats:title> <jats:p>Objectives: Cotinine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) are widely used biomarkers for tobacco-derived nicotine and the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), respectively. The discrepancy between cotinine levels in relation to disease risk comparing active versus passive smoking suggests a nonlinear tobacco smoke dose-response and/or that cotinine is not providing an accurate measure of exposure to the toxic constituents of secondhand tobacco smoke.</jats:p> <jats:p>Methods: Cotinine and NNAL were measured in the urine of 373 active smokers and 228 passive smokers.</jats:p> <jats:p>Results: Average cotinine levels were 1,155 (interquartile range, 703-2,715) for active smokers and 1.82 (0.45-7.33) ng/mg creatinine for passive smokers. Average NNAL levels were 183 (103-393) and 5.19 (2.04-11.6) pg/mg creatinine, respectively. NNAL/cotinine ratio in urine was significantly higher for passive smokers when compared with active smokers (2.85 × 103 versus 0.16 × 103, P &lt; 0.0001).</jats:p> <jats:p>Conclusions: Passive smoking is associated with a much higher ratio of NNAL/cotinine in the urine compared with active smoking.</jats:p> <jats:p>Impact: Cotinine measurement leads to an underestimation of exposure to the carcinogen NNK from secondhand smoke when compared with active smoking. Cancer Epidemiol Biomarkers Prev; 19(11); 2795–800. ©2010 AACR.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ